MEDPLUS2024-01-012024-03-31 MEDPLUS2024-01-012024-03-31 MEDPLUS2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member MEDPLUS2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member MEDPLUS2024-03-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543427 MEDPLUS NOTLISTED Medplus Health Services Limited Equity 2023-04-01 2024-03-31 2024-05-28 2024-03-30 INR Millions Yearly 14:30:00 15:55:00 2024-05-28 2024-05-28 true Cash Flow Indirect Declaration of unmodified opinion Single segment In accordance with Ind AS 108, Operating Segments, segment information has been given in the consolidated financial statements of MedPlus Health Services Private Limited and therefore no separate disclosure on segment information is given in these standalone financial statements 2024-01-01 2024-03-31 Audited Standalone 1483680000.00 18980000.00 1502660000.00 119670000.00 1010690000.00 -6260000.00 116750000.00 21090000.00 64020000.00 113480000.00 1439440000.00 63220000.00 0.00 63220000.00 -890000.00 -35050000.00 -35940000.00 0.00 99160000.00 0.00 0.00 0.00 0.00 99160000.00 -5150000.00 94010000.00 0.00 0.00 239070000.00 2 0.83 0.83 0.00 0.00 0.83 0.83 1. The above audited standalone financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These audited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on May 28, 2024. These financial results have been audited by the Statutory Auditors of the Company and the auditors have expressed an unqualified opinion on the same. 2. During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000.00 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from 23 December 2021. The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below: Objects as per Prospectus Planned utilisation as per Prospectus Utilisation up to March 31, 2024 Unutilised amount as on March 31, 2024* i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements 4,671.70 4,671.70 - ii) General Corporate Purposes 1,111.03 448.53 662.50 Total 5,782.73 5,120.23 662.50 * The aforesaid unutilised proceeds of Rs. 662.50 million have been placed as fixed deposits with bank. 3. As per Ind AS 108 'Operating segments', the Company has disclosed the segment information as part of the consolidated financial results. 4. During the year ended March 31, 2024, with respect to the merger between the Company and MHS Pharmaceuticals Private Limited (MHS), a wholly owned subsidiary, the Company has received approval from equity shareholders and trade creditors in a meeting held on December 15, 2023 pursuant to NCLT order dated November 7, 2023. The Company has filed the final petition for approval under Section 232 Read with Section 230 of the Companies Act, 2013 dated December 26, 2023. Further, the hearing for final approval has been adjourned to June 13, 2024. Consequent adjustments in the financial statements will be made on receipt of requisite approval. 5. During the quarter and year ended 31 March 2023, The Company has recognised provision for impairment of its investments and loans receivable (including interest) from Kalyani Meditimes Private Limited, a Subsidiary, to the tune of Rs.56.33 million. The Management during the said period, has also reversed impairment provision made during the prior periods to the tune of Rs.125.77 million in respect of investments in another subsidiary, WynClark Pharmaceuticals Private Limited. These amounts were recorded/reversed pursuant to management assessment of the future cash flows of the underlying subsidiary Companies and their historic and projected profitability. 6. The results for the quarter ended March are the balancing amounts between the figures in respect of the full financial year and the published figures upto the third quarter of the respective financial year. 7. The earnings per equity share for the quarters are not annualised. 8. Pursuant to an assessment of future profitability of the operations of the Company, the management has recognized deferred tax assets amounting to Rs. 33.59 million during the quarter and year ended 31 March 2024 on unused business losses and unabsorbed depreciation of earlier years Single segment 2023-04-01 2024-03-31 Audited Standalone 4670300000.00 72930000.00 4743230000.00 445230000.00 3073950000.00 -8830000.00 436060000.00 84020000.00 241700000.00 400690000.00 4672820000.00 70410000.00 0.00 70410000.00 9650000.00 -35050000.00 -25400000.00 0.00 95810000.00 0.00 0.00 0.00 0.00 95810000.00 4350000.00 100160000.00 0.00 0.00 239070000.00 2 0.00 0.80 0.80 0.00 0.00 0.80 0.80 Other Expenses 113480000.00 Other Expenses 400690000.00 1090750000.00 3520000.00 0.00 25770000.00 9297160000.00 0.00 71890000.00 9369050000.00 33590000.00 840310000.00 11362990000.00 139610000.00 0.00 658330000.00 130010000.00 494250000.00 0.00 247570000.00 1530160000.00 89520000.00 1759290000.00 13122280000.00 239070000.00 11487230000.00 11726300000.00 11726300000.00 0.00 0.00 15480000.00 822040000.00 837520000.00 0.00 179480000.00 209760000.00 389240000.00 149990000.00 19230000.00 558460000.00 1395980000.00 13122280000.00 Standalone Groupings for XBRL File 1 Other Non- Current Asset a ROU Asset 800.24 b Other tax assets 38.23 c Other non-current assets 1.84 Total 840.31 2 Other Non-current liabilities a Lease liabilities 822.04 Total 822.04 3 Other current liabilities a Lease liabilities 63.68 b Contract liabilities 59.02 c Other current liabilities 27.29 Total 149.99 84020000.00 -72740000.00 0.00 0.00 16130000.00 0.00 -2890000.00 -287340000.00 0.00 0.00 0.00 6270000.00 0.00 241700000.00 0.00 -7870000.00 0.00 66840000.00 0.00 0.00 0.00 58020000.00 15450000.00 0.00 0.00 0.00 0.00 27940000.00 0.00 29490000.00 99900000.00 0.00 0.00 0.00 23200000.00 0.00 76700000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10640000.00 123900000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 42480000.00 0.00 -173480000.00 0.00 -244260000.00 0.00 0.00 0.00 0.00 0.00 0.00 72290000.00 0.00 0.00 0.00 0.00 47730000.00 0.00 84020000.00 0.00 0.00 -59460000.00 -227020000.00 0.00 -227020000.00 357030000.00 130010000.00 -3690000.00 5810000.00 1460000.00 1460000.00 0.00 0.00